Login:
 
Practitioner 2012; 256 (1755): 11-12

Intermittent ADT an option for advanced prostate cancer

31 Oct 2012Pais-up subscribers

Compared with continuous treatment intermittent androgen deprivation therapy (ADT) can improve patients’ quality of life and does not adversely affect survival, a study in the NEJM concludes. [With external links to current evidence and summaries]

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .

To buy this article (£25+tax) copy the article citation above and click Buy article